[Federal Register Volume 79, Number 49 (Thursday, March 13, 2014)]
[Notices]
[Page 14299]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-05504]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Pharmacore, Inc.

    By Notice dated September 27, 2013, and published in the Federal 
Register on October 25, 2013, 78 FR 64017, PharmaCore, Inc., 4180 
Mendenhall Oaks Parkway, High Point, North Carolina 27265, made 
application by letter to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of Noroxymorphone (9668), a basic 
class of controlled substance listed in schedule II.
    The company plans to manufacture the listed controlled substance as 
active pharmaceutical ingredients (API) for clinical trials.
    No comments or objections have been received. The DEA has 
considered the factors in 21 U.S.C. 823(a) and determined that the 
registration of PharmaCore, Inc., to manufacture the listed basic class 
of controlled substance is consistent with the public interest at this 
time. The DEA has investigated PharmaCore, Inc., to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 
1301.33, the above named company is granted registration as a bulk 
manufacturer of the basic class of controlled substance listed.

    Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2014-05504 Filed 3-12-14; 8:45 am]
BILLING CODE 4410-09-P